HomeSearch Results - C-CPI-2404 Accurate Study Material – Find Shortcut to Pass C-CPI-2404…
Search Results - C-CPI-2404 Accurate Study Material – Find Shortcut to Pass C-CPI-2404 Exam 👄 The page for free download of ⏩ C-CPI-2404 ⏪ on ➠ www.pdfvce.com 🠰 will open immediately 🦏C-CPI-2404 Exam Score
…of your password or Account, you agree to notify Us immediately at info@missionbio.com. 5.2. There are several requirements related to the creation and maintenance of an Account: You must be…
…of the study. Thank you both for joining. Ash Alizadeh, MD, PhD: I’ll give a big picture overview and then have Mark dig into the details. This study was…
…to them, and it may for you too. We need to find more ways to align across the organization. Great companies are as buttoned up with their internal communications as…
…information; and (iii) download Tapestri Insights™ software and publicly available data sets. Communications. If you contact us directly, we may receive additional information about you. For example, when you contact…
…level. Using our Tapestri Platform, researchers are performing comprehensive multi-omics analyses and detangling the complexities of diseases, like cancer, at an unprecedented level of detail. Although the day specifically commemorates…
…ability to accurately measure and understand these events. Furthermore, since “cells” are the functional units of gene editing products, it is prudent to measure the co-occurrences of editing results and…
…Warranty) will be free from material defects in materials and workmanship under normal use for a period of one (1) year from the date Seller makes the device available for…
…To learn more about Mission Bio and how it’s moving precision medicine forward, visit www.missionbio.com. About Mission Bio Mission Bio delivers targeted solutions for high impact applications with the…
…tissue. Snap freezing or OCT embedding tissues are the most common forms of preservation. However, these methods add an additional layer of complexity to sample preparation. Some researchers have addressed…
…delivering single-cell resolution multi-omics tools to accelerate discoveries and improve time-to-market for new therapeutics, announced today a new peer-reviewed study published using the Tapestri Platform’s single-cell multi-omics solution to accurately…
…day come to be? As many of us are familiar, when it comes to participation in science there is a rift between the genders. Only about a third of scientific…
…please visit missionbio.com. Media Contact Consort Partners for Mission Bio missionbio@consortpartners.com Mission Bio Announces High Precision Detection of Variants For Tapestri® Platform in NIST Genome Editing Consortium Initial Study…
The study, published in Nature Communications, leverages the Tapestri Platform to illustrate the single-cell atlas of acute myeloid leukemia (AML) with multi-omics, describing the clonality underlying therapeutic resistance SOUTH…
…on roller coasters and any type of thrill-seeking adventure. I also like to listen to and attend musical theatre performances. In my free time, I enjoy working out and doing…
…impede relapse. The study was led by research teams University of California, San Francisco (UCSF), Johns Hopkins University, and University of Pennsylvania. “Cancer is complex. It is heterogeneous…
…outcomes in the fight against cancer — and that’s the most meaningful benchmark of all.” The funding round comes a year after the company’s commercial launch of the Tapestri Platform…
…The online version of the full peer-reviewed study can be found here. To learn more about Mission Bio and how it’s moving precision medicine forward, visit www.missionbio.com. About Mission…
While California has extended its shelter-in-place order through the end of May, some San Francisco, Bay Area laboratories might be permitted to re-open in a few weeks. As we think…
…Women across all departments — from R&D to the commercial team— are a key reason why the company is rapidly developing single-cell solutions for cutting-edge cancer research. We continue to…
…study shows that Tapestri accurately uncovered complex clonal evolution within the AML tumors, unobservable with traditional bulk Next-Generation Sequencing (NGS). Tapestri was able to perform analysis in just two days…
…cell malignancies, such as chronic lymphocytic leukemia (CLL). The enzyme, Bruton’s tyrosine kinase (BTK) is a key component of B-cell antigen receptor signaling, and thus an important therapeutic target. The…
…stage zero, if you will. That’s, I think, really exciting potential for the field. Ania: I completely agree. Now, one thing that I’m very passionate about is accurate science communication…
…started this study, that wasn’t something that we were really thinking about yet. And I think, as we started to get the data, it just opened up a huge range…
…be designed quickly and easily to complement Tapestri Single-Cell DNA Catalog Panels. The announcements come on the heels of a peer-reviewed publication by Mission Bio and MD Anderson Cancer…
…for cancer and other rare diseases. To learn more, visit missionbio.com. Media Contact Consort Partners for Mission Bio missionbio@consortpartners.com New Nature Study Uses Mission Bio’s Tapestri Platform for Single-nuclei…
…every molecule in a cell together, providing a comprehensive understanding of activity from a single sample. Tapestri is the only commercialized multi-omics platform capable of analyzing DNA and protein simultaneously,…
…child, I was fascinated by biology, medicine, and nature. I was curious and eager to discover the mechanisms behind any process. Reading and ballet were also my big passions. I…
Darrin Crisitello, Chief Commercial Officer, Mission Bio At Mission Bio, everyone at the company is pushing forward with science that can improve patient care in a meaningful way. Upon recently…
…Composite complete remission with IVO + VEN + AZA versus IVO + VEN was 90% versus 83%. Among measurable residual disease (MRD)–evaluable patients (N = 16), 63% attained MRD-negative remissions;…
…a grant from the Chan-Zuckerberg Foundation. Abate’s proprietary research in high throughput and droplet technology helped lay the foundation for Mission Bio’s single-cell genomics system. The award to Abate immediately…
…and diagnostics companies around the world to develop treatments and eventually cures for cancer. To learn more, visit missionbio.com. Media Contact: Consort Partners for Mission Bio missionbio@consortpartners.com A New…
…simple reporting– making it easier than ever to glean insights about zygosity of edits, co-occurrence of multiplex edits, on- vs. off-target edits, in combination with surface protein expression. If you…
The study, led by Ross Levine of Memorial Sloan Kettering Cancer Center, leverages the Tapestri Platform’s unique DNA + Protein capabilities to elucidate the complexity of acute myeloid leukemia (AML)…
…cell populations at unprecedented resolution compared to traditional bulk sequencing approaches. Starting the design process is easy, and panel designs can be completed within a matter of minutes. To begin,…
…the Tapestri® Single-cell Multi-omics MRD (scMRD) for AML Summit to be held in New York on August 16, 2022. The company plans its full commercial launch for single-cell measurable residual…
…The company has partnered with BioLegend, a global leader in protein antibody and reagent manufacturing, to co-develop the first commercial solution for combined DNA and protein analysis at the single-cell…
…Tapestri single-cell DNA sequencing work with the larger cancer community. AACR also marked the start of our Single-Cell DNA-Seq Grant Challenge. Applications are open now through April 30th, 2019 and…
…With this partnership, we can now offer complete support from preclinical and biomarker discovery through to clinical trials and commercialization.” “LabCorp’s leadership in precision medicine is based on a combination…
…Company’s lead compound, rigosertib, are aimed at what the Company believes are unmet medical needs of patients with MDS. For more information, please visit http://www.onconova.com. About Rigosertib Rigosertib, Onconova’s lead…
…disease lies in its complexity. Tumors are composed of subpopulations of cells — or clones — that each has a unique collection of mutations. It is this heterogeneity coupled with…
…key pathological feature. Tumors comprise multiple genetically-distinct cell populations, called clones. And the mutations of each clone are often of clinical significance. For instance, some co-mutations may give a clone…
…clones expanding (green dots) and shrinking (red dots) over time, and then assess the commonalities between the green dots and commonalities amongst the red dots. This example shows pre-treatment samples…
…accurate and comprehensive analysis to ensure that the edited cells are safe and effective. Here we discuss the importance of genome editing analysis for cell therapy development and how single-cell…
…cancer and other rare diseases. To learn more, visit missionbio.com. Media Contact Consort Partners for Mission Bio missionbio@consortpartners.com Mission Bio’s Tapestri Platform Used in Melanoma Study on Therapy Resistance…
…clinical utility.” To learn more about Mission Bio and the Tapestri® Platform, please visit www.missionbio.com. About Abiosciences Abioscience is a biotechnology company with a global vision founded in…
…will continue to improve and is going to be more accurate when we define the mutational events in the tumor populations.” – Dr David Coffey, MD New Tools in the…
…Center Dr. Kiyomi Morita from Dr. Koichi Takahashi’s group at MD Anderson opened up Saturday morning oral abstract presentations for acute myeloid leukemia (AML), presenting the largest patient research study…
Inactive state-selective KRAS(G12C) inhibitors1-8 demonstrate a 30-40% response rate and result in approximately 6-month median progression-free survival in patients with lung cancer9. The genetic basis for resistance to these first-in-class…
…cell. Characterize genomic heterogeneity using a single platform, with comprehensive single-cell SNV and CNV analysis to co-detect all the changes in our blueprint. When determining the clonal heterogeneity across a…
…Sequencing over 300,000 cells, the 38-sample study was led by Ravi Majeti, M.D., Ph.D. and his team at Stanford University and published in Blood Advances. It is the first-ever study…
…www.missionbio.com. About Mission Bio Mission Bio is a life sciences company that accelerates discoveries and cures for a wide range of diseases by equipping researchers with the tools they…
…sensitive and customizable solution that is fully supported to enable meaningful discoveries. Media Contact: Andrea Vuturo andrea@vuturo.com (415) 689-8414 Mission Bio: Rebecca Galler Senior Vice President, Marketing galler@missionbio.com (303) 887-7658…
…About Mission Bio Mission Bio is a leading life science company, specializing in the advancement of single-cell DNA and multi-omic analysis. The company’s Tapestri Platform is unique in its capabilities,…
…a primary focus on oncology. A study published in Nature Communications showcases the platform’s utility in dissecting acute myeloid leukemia at the single-cell level, demonstrating how patient stratification based on…
…current treatment paradigm by combining novel therapies to prevent or delay resistance to these novel agents.” These insights underscore the power of single-cell DNA analysis to provide high-resolution monitoring…
…our knowledgeable field and support team as they tackle any single-cell question in Mission Bio’s Open Office Hours. Get answers to your single-cell technology questions and learn from other users….
…clinical and enterprise computing security best practices (Reference; https://aws.amazon.com/compliance/soc-faqs/). Mission Bio’s AWS security policies MissionBio provides an AWS-based platform for client use following best practices in the following areas Identity…
…determining CQAs 56% feel dissatisfied with their characterization approach 81% agree better characterization would reduce risk of holds Download The cell and gene therapy characterization survey report to learn more….
…they’re getting sued by the FTC to stop the acquisition. They mentioned all these competitors that are coming up on the sequencing landscape and some new ones that are now…
…the tumor microenvironment. Importantly, the presence of monocytic MDS-PA at diagnosis anticipated greater risk of hematologic toxicity and was independently associated with inferior progression-free survival (hazard ratio, 1.5; P =…
…same editing regimen can yield distinct combinations of edits, varying not only across multiple on-target sites but also between on-target and off-target locations. The result is that genome editing of…
…single-cell DNA sequencing, on the other hand, can be used to dissect tumor architecture with a high amount of detail — including zygosity, co-mutations, and clonal composition. This study adds…
…MRD detection. In their study, the researchers found that T-ALL samples were polyclonal, with NOTCH1 mutations commonly observed, and minor clones at diagnosis sometimes became major clones at later disease…
…She presented a comparison of a lab and clinical study where there was a difference in chromosome loss after T cell editing attributed to the difference to the order of…
…combined with a false-negative rate as low as 7% scTAM-seq can be combined with somatic mutation and cell surface expression analysis to enable a much richer characterization of tumor heterogeneity…
Single-cell DNA methylation profiling currently suffers from excessive noise and/or limited cellular throughput. We developed scTAM-seq, a targeted bisulfite-free method for profiling up to 650 CpGs in up to 10,000…
…other cell therapies, where engineering is becoming increasingly complex and therapies in development contain multiple modifications. The new assay consolidates VCN with transduction measurements – reducing time, labor, and sample…
…a cell together, providing a comprehensive understanding of activity from a single sample. Tapestri is the only commercialized multi-omics platform capable of analyzing DNA and protein simultaneously from the same…
…company’s Tapestri Platform is unique in its capabilities, offering an unparalleled level of granularity and precision that is critical for complex research areas such as cancer studies, pharmaceutical development, and…
…perform single-cell vector copy number (VCN) and transduction measurements simultaneously– including VCN per transduced cell, providing more accurate characterization within a cell population compared to bulk measurements. This comprehensive analysis…
…trying to develop a new diagnostic study for children with leukemia. And that introduced me to a company called ArcherDX probably around 2016, 2017. They had their own chemistry for…
…observed at diagnosis in both cohorts; however, decreasing clonal diversity at remission was significantly associated with longer relapse-free survival. These results show the power of SCS in investigating AML MRD…
…of the Centre for Genomic Regulation (CRG) in Barcelona teamed up to develop a novel high-throughput, high-confidence targeted bisulfite-free method for analyzing DNAm in single cells, now published in Genome…
…Angeles with a Bachelor of Science in Psychobiology and a minor in Entrepreneurship. I am passionate about sustainable fashion, and I enjoy going to flea markets and thrifting at vintage…
…But recent studies have warned about the dangers of unintended genome alterations and how they could negatively impact patient outcomes. Altering genetic material is complex, and researchers need to be…
…into host cells using viral or non-viral vectors. The accurate measurement of gene transfer is critical to the development of therapeutic agents and is a key attribute for assessing their…
…into host cells using viral or non-viral vectors. The accurate measurement of gene transfer is critical to the development of therapeutic agents and is a key attribute for assessing their…
Many cell and gene therapies introduce transgenes into target cells utilizing viral and nonviral vectors. The accurate assessment of transduction/ transfection efficiency and the number of vector copies are critical…
…transgenes into host cells using viral or non-viral vectors. The accurate measurement of gene transfer is critical to the development of therapeutic agents and is a key attribute for assessing…
…vectors. The accurate measurement of gene transfer is critical to the development of such therapies and is critical for assessing their safety and efficacy. Yet, conventional methods for measuring gene…
…ways of treating patients and advancing precision therapeutics.” To learn more about Mission Bio and the Tapestri platform, please visit www.missionbio.com. About Mission Bio Mission Bio is a life sciences…
…somatic mutations in MAP3K3 or PIK3CA – common in patients with CCMs – co-existed in the same cells. Single-cell DNA sequencing with Tapestri found co-occurring mutations in the cells of…
…by The Scientist, as well as utilized by researchers at MD Anderson Cancer Center (MDACC) for the largest single-cell study completed to date. With Mission Bio, researchers have a highly…
…Tapestri Platform. The award-winning technology has been adopted by Agios, LabCorp, Onconova Therapeutics, and other companies for more efficient clinical trials. The full peer-reviewed study can be found here….
…Genome Editing Solution, enabling researchers to conduct more comprehensive analysis of genome editing outcomes that also includes on- and off-target edit confirmation, zygosity, and co-occurrence of edits at single-cell resolution….
Multiple myeloma, a complex and incurable cancer of plasma cells, poses a significant challenge to modern medicine. However, the emergence of cutting-edge technologies in genomics has opened up new avenues…
…heterogeneity of the leukemia cells of 20 ALL cases at diagnosis and monitored the clonal evolution during chemotherapy treatment. Specifically, the lab designed a custom ALL panel and obtained accurate…
…panel and obtained accurate single-nucleotide variant and small insertion-deletion mutation calling for 305 amplicons covering 110 genes in about 4400 cells per sample and time point. A total of 108,188…
…relapse. Equipped with single-cell DNA sequencing and other innovative technologies, oncologists and researchers are working hard to bring better treatment to blood cancer patients. References https://www.lls.org/facts-and-statistics/facts-and-statistics-overview https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21654 https://www.medscape.com/answers/199425-167660/what-is-the-prognosis-of-chronic-myelogenous-leukemia-cml …
…better study therapy response, resistance, and relapse. Metastatic cancer in solid tumors leads to the clonal evolution of mutations at different sites in the body. Understanding the phylogeny of mutations…
Genome Editing. Because zygosity and co-occurrence of multiple on and off-edit targets make a difference It is time to unlock biological complexity Genome editing libraries are powerful tools to advance…
…to treat is that the disease inherently has many different molecular drivers and indicators. MM is a genetically complex malignancy comprised of immunoglobulin translocations, focal and genome-wide CNVs, complex genomic…
…immune selection in HIV-1 reservoir cells,” published on January 4 in Nature. To learn more about Mission Bio and the Tapestri® Platform, please visit www.missionbio.com. About Mission Bio…
…peer-reviewed study validating the technology that powers our Tapestri Platform. The study marks the first-ever application of a commercial high throughput single-cell DNA sequencing technology to patient samples. Together, MD…
…failure after frontline venetoclax combinations in older patients with AML Molecular basis for treatment resistance or durable remission in older patients with AML given venetoclax combination therapy. Ediriwickrema A et…
…genetics, and is passionate about uncovering the underlying mechanisms of diseases like cancer. She is the first author of a paper in Nature Medicine entitled “Clinical evolution, genetic landscape, and…
Find the key signatures of cancer. Cancer is a complex disease, where behind its complexity lie meaningful insights to source and its cure. Bulk sequencing erases cancer’s fundamental units, individual…
…an extremely small number of subclones – about five cells – and detected years before final expansion. The findings could enable researchers to develop strategies targeting these dormant subclones to…
…of residual or recurring cancer.” To learn more about Mission Bio and the Tapestri® Platform, please visit www.missionbio.com. About Mission Bio Mission Bio is a life sciences company…
…Bio and the Tapestri® Platform, please visit www.missionbio.com. About Mission Bio Mission Bio is a life sciences company that accelerates discoveries and cures for a wide range of diseases…
…they impact disease progression and treatment resistance. For example, a study recently published in Blood Advances by researchers at University of California, San Francisco (UCSF), Johns Hopkins University, and University…
Single-cell analysis has enabled the comprehensive characterization of tumor samples, especially for blood cancers like leukemia. Using the Tapestri Platform, for instance, enables researchers to dissect the clonal structure of…
Hematology. Because single-cell insights are critical to determining the source of resistance, response, and relapse It is time to get a holistic view of cancer The complexity of cancer is…
…strategic partnership with Sequanta Technologies Co., Ltd. to provide services to cell and gene therapy companies in mainland China. To learn more, visit missionbio.com. About Mission Bio Mission Bio is…
…can unravel the mechanisms that drive disease correction and disease progression, visit missionbio.com. ———————————————————————– 1 https://www.cancer.gov/research/key-initiatives/ras/about About Mission Bio Mission Bio is a life sciences company that accelerates discoveries…
…in research institutes, hospitals, and pharmaceutical companies worldwide, to promote adoption of innovative single-cell omics technologies to clinical diagnosis, drug development, and health management. For more information, visit www.sequmed.com. …
…life science research, healthcare, and agriculture. For more information about S2 Genomics and the Singulator 100, visit www.S2Genomics.com. Media Contact Consort Partners for Mission Bio missionbio@consortpartners.com Mission Bio…
…visit https://go.missionbio.com/ash-2022. To meet us in person, please visit us all week at Booth 2014. To learn more about Mission Bio and the Tapestri® Platform, please visit www.missionbio.com. …
…April. 4, 2024 – Mission Bio, a leader in single-cell multiomic solutions for precision medicine, today introduces sample multiplexing features for the company’s Tapestri Platform. These features enable the combination…
… Darrin Crisitello joins the Mission Bio team as Chief Commercial Officer with over 19 years of experience in commercial leadership and business development. Previously, Crisitello led the global clinical…
…bone marrow single-cell DNA sequencing revealed multiple competing SGR events in individual patients. Our findings demonstrate that SGR is common in SAMD9/9Lmut MDS and exemplify the exceptional plasticity of hematopoiesis…
Systematic evaluation of the impact of genetic variants is critical for the study and treatment of human physiology and disease. While specific mutations can be introduced by genome engineering, we…
…research organizations, and biopharma companies can utilize the scMRD assay for AML for proof-of-concept study research programs ahead of full-scale commercialization. For more information, visit https://go.missionbio.com/scMRD-AML-EA. [1] Relapse in…
New study led by University Cancer Center of Toulouse shows high frequency of RAS/RAF subclone mutations in MM SOUTH SAN FRANCISCO, Calif., April 30, 2024 – Mission Bio, a…
…nongenetic mechanisms of resistance are unclear. This study investigated these two trajectories in PDX models that had been subjected to combination therapy targeting the MAPK pathway. The team assessed whether…
…a wide breadth of topics – bringing together the cancer research community to inspire innovation and build knowledge, connections and collaborations. We enjoyed inspiring scientific communications at our booth and…
Untangle the Complexity of Cancer. Determine the sources of resistance, response, and relapse Tapestri single-cell DNA panels and protein panels are highly sensitive and customizable panels that enable true multi-omics…
…To learn more about Mission Bio and the Tapestri® Platform, please visit www.missionbio.com. About Mission Bio Mission Bio is a life sciences company that accelerates discoveries and cures for…
…full survey report here: https://go.missionbio.com/cgt-survey-report To learn more about Mission Bio and the Tapestri® Platform, please visit www.missionbio.com. About Mission Bio Mission Bio is a life sciences company…
…the Tapestri® Platform, please visit www.missionbio.com. About Mission Bio Mission Bio is a life sciences company that accelerates discoveries and cures for a wide range of diseases by equipping…
…concern, the pressing need for effective SCD treatments urges continued research, monitoring, and careful consideration of the benefits against the risks in advancing such transformative therapies. Sources https://www.genengnews.com/topics/genome-editing/crispr-prime-time-fda-advisory-committee-evaluates-vertex-exa-cel-therapy-for-sickle-cell-disease/ https://endpts.com/uk-approves-vertex-crispr-therapy-for-sickle-cell-disease-beta-thalassemia-in-world-first/…
…medicine, announced the commercial launch of the Tapestri® Single-cell MRD (scMRD) AML Multiomics Assay. The company designed the scMRD AML Multiomics Assay to bring unprecedented resolution to disease relapse and…
…unmatched resolution, please visit missionbio.com/products/platform/. About Mission Bio Mission Bio is a leading life science company, specializing in the advancement of single-cell DNA and multiomics analysis. The company’s Tapestri…
…researchers with high-throughput, single-cell multiomic analysis of genome-wide CNVs, combined with automated reporting and multiplexing capabilities to ensure even more accessibility. Compared to current methods, the solution equips CGT developers…
…– Provides training for preventing unconscious bias & discrimination 3. Stem Study– Women & Minorities in STEM – Contains a list of professional networking groups – Details advocacy & mentorship…
…a definitive cure remains elusive. Over the past century, the array of techniques to study diseases has increased almost exponentially, with disease modeling emerging as a pivotal avenue. Patient-derived xenografts…
Untangle Single-cell SNV and Indel Insights. The Tapestri Platform is the first and only single-cell multi-omics platform to simultaneously detect single nucleotide variants (SNVs) and indels from the same cell….
…companies looking to advance their understanding of cancer and develop more durable therapies with Mission Bio, visit missionbio.com. About Mission Bio Mission Bio delivers targeted solutions for high-impact applications…
…sequencing can provide information about leukaemia biology and prognosis, it cannot distinguish which mutations occur in the same clone(s), accurately measure clonal complexity, or definitively elucidate the order of mutations….
Single-cell sequencing is like looking at the galaxy with the Hubble telescope. It provides the ability to drill down into the complexity of a cell in an environment where each…
DNA is the template for human biology and the point where a single mutation initiates disease. By taking a holistic approach, we can investigate every part of the cell and…
…physics and applied it to droplet manipulation, ultimately co-developing the technology that became the core of Mission Bio. He continues to be interested in tackling complex, interdisciplinary problems with physics….
Anjali is Chief Product Officer at Mission Bio. She has launched cutting-edge products in DNA sequencing, RNA ISH, and multiplexed tissue imaging solutions. She has successfully developed and executed product…
…leadership roles at companies in the genomics space and in stem cells and regenerative medicine. Prior to joining Mission Bio, George led the sales team at Cellular Dynamics, where he…
Hannah Viernes leads the marketing team and has over 15 years of experience across life sciences tool companies in both product management and marketing. Most recently, Hannah led the Global…
…somatic hematopoietic clones arise early in life, most commonly harboring heterozygous mutations in EIF6 or TP53. We show that germline SBDS deficiency establishes a fitness constraint that drives selection of…
Studies of acute myeloid leukemia rely on DNA sequencing and immunophenotyping by flow cytometry as primary tools for disease characterization. However, leukemia tumor heterogeneity complicates integration of DNA variants and…
Vascular malformations are considered monogenic disorders that result in dysregulated vessel growth. Cerebral cavernous malformations (CCMs) arise owing to inactivation of the endothelial CCM protein complex required to dampen MEKK3…
Allosteric inhibitors of mutant IDH1 or IDH2 induce terminal differentiation of the mutant leukemic blasts and provide durable clinical responses in approximately 40% of acute myeloid leukemia (AML) patients with…
…alterations and increased sensitivity to extracellular signal-regulated kinase inhibition. These findings identify an approach that abrogates the nongenetic resistance trajectory in melanoma and demonstrate that the cellular composition of MRD…
Ben Schroeder has over 20 years of experience in biotechnology R&D. His focus has been novel genomic technologies spanning small start-ups to large established companies. Ben started his career at…
Marlene Martinez leads the human resources team focusing on attracting, retaining, and developing our talent as we scale as an organization. She has over 15 years of experience in human…
Despite high initial response rates, acute myeloid leukemia (AML) treated with the BCL-2–selective inhibitor venetoclax (VEN) alone or in combinations commonly acquires resistance. We performed gene/protein expression, metabolomic and methylation…
…familial CCM. Furthermore, we find identical PIK3CA mutations in CCMs and adjacent developmental venous anomalies (DVAs), a common vascular malformation frequently found in the vicinity of sporadic CCMs. However, somatic…
Todd Druley, MD, PhD established his career as a board-certified pediatric oncologist and tenured physician-scientist in molecular genomics at Washington University School of Medicine and St. Louis Children’s Hospital. Todd’s…
…unknown. We characterized the whole genome, epigenome and transcriptome, combined with single-cell DNA/RNA-sequencing analyses and functional experiments, of 19 cases of CLL developing RT. Studying 54 longitudinal samples covering up…
Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. Here, using whole-genome, exome and transcriptome sequencing of 2,754 childhood patients with ALL, we find that, despite a generally low…
…a phenotypic signature primarily characterized by upregulation of surface markers promoting cell survival, including CD44, CD28, CD127 and the IL-21 receptor. Together, these results suggest compartmentalized phenotypic signatures of immune…
Despite insights gained by bulk DNA sequencing of cancer it remains challenging to resolve the admixture of normal and tumor cells, and/or of distinct tumor subclones; high-throughput single-cell DNA sequencing…
…base editing mutagenesis. Deep mutagenesis of JAK1 with cytidine and adenine base editors, combined with pathway-wide screens, reveal loss-of-function and gain-of-function mutations, including causal variants in hematological malignancies and mutations…
Adam is a co-founder and the interim Chief Operating Officer of Mission Bio. His proprietary research in high throughput and droplet technology helped lay the foundation for Mission Bio’s single-cell…
Pediatric acute myeloid leukemia (pAML) is typified by high relapse rates and a relative paucity of somatic DNA mutations. Although seminal studies show that splicing factor mutations and mis-splicing fuel…
Recent data suggest that NPM1-mutated AMLs are heterogeneous in terms of co-mutations and expression of transcriptomic programs and surface proteins. Such heterogeneity may reflect a variable differentiation blockade of leukemic…
…To learn more about Mission Bio and the Tapestri® Platform, visit www.missionbio.com. About Mission Bio Mission Bio is a life sciences company that accelerates discoveries and cures for…
…or are not applicable to targeted sequencing. Here, we develop COMPASS, a computational method for inferring the joint phylogeny of SNVs and CNAs from targeted scDNAseq data. We evaluate COMPASS…
…building high-growth companies. His prior roles include founder, CEO, executive board director, division president at large publicly traded and PE-backed companies such as Fortis Life Sciences, LGC, PerkinElmer, Life Technologies,…
Roman is the Chief Commercial Officer at Mission Bio. Roman has more than 25 years of experience in diagnostics and life sciences research, including previous roles as EVP and General…
…the current workflow. With this latest capability, Mission Bio’s Tapestri® Platform now stands as the first and only commercial platform for single-cell DNA analysis, with comprehensive insight into mutations and…
…it with additional experts as we shine a new light across the solid tumor landscape.” To learn more, visit missionbio.com. About Mission Bio Mission Bio is a life sciences company…
Mission Bio at EHA! We are back from the 2019 European Hematology Association conference in Amsterdam, what a great meeting it was for the cancer community. There were many exciting…
…and resistance. Cancer is an inherently complicated disease, but we can help simplify the study of it. Through these tools, we’re empowered with a depth of understanding to take us…
…treatment, which acted as a barrier to the long-term success of targeted therapies. The study highlights clinically relevant, existent and therapy-driven mutations that will impact future treatment strategies and combination…
…Nature Communications, their study established a single-cell genomics atlas of AML samples, providing previously undiscovered insight into disease evolution and treatment resistance. That was followed in short order by a…
…cancers, acute myeloid leukemia (AML) is a highly heterogeneous disease. Tumors are often composed of cells with different combinations of mutations and genetic alterations. They are also phenotypically diverse, with…
…defective junctional components. They’re malformed vessels, but they’re very discrete lesions. They cause either a slow leak or oozing or hemorrhage or can overtly bleed. They cause cerebral events, like…
…to identify leukemia MRD. Question: Is it possible to distinguish AML from CHIP clones using single-cell proteogenomic profiling? Methods: This study used Mission Bio’s Tapestri Platform to perform single-cell DNA…
…cancers with aberrant TP-53. However, in our study, TP53-mutated or -deficient myeloid and lymphoid leukemias outcompeted isogenic controls with intact TP-53, unless sufficient concentrations of BH3-mimetics targeting BCL-2 or MCL-1…
…therapy, because there, for example, in the FLT3 inhibitor study that I showed. With that patient’s tumor, there was a clone that did not harbor a mutant target of Gilteritinib…
…distinguish MRD clones from preleukemic or clonal hematopoiesis (CH) clones. This distinction is crucial for accurately predicting the risk of relapse. Single-cell MRD (scMRD) assay can more accurately characterize MRD…
…screens, and gene-edited based cell and gene therapies. With the ability to provide high-throughput analysis at single-cell resolution, this innovative solution is a game-changer through its comprehensive, multi-omic approach. The…
…Avet-Loiseau from Institut universitaire du cancer de Toulouse Oncopole and Dr. Cedric Dos Santos from Genentech. The study combined simultaneous genotyping (SNV/Indels/CNV’s), immunophenotyping and VDJ clonotyping on the Tapestri platform…
Earlier this year, Dr. Robert Bowman, Assistant Professor of Cancer Biology at the University of Pennsylvania, presented a webinar where he discussed how single-cell analysis can be leveraged to study…
…genetic analysis businesses at a multi-billion dollar company, I’m excited by the tremendous potential in Mission Bio’s industry-first multi-omics capabilities – both to accelerate our understanding of cancer and to…
…a cell together, providing a comprehensive understanding of activity from a single sample. Tapestri is the only commercialized multi-omics platform capable of analyzing DNA and protein simultaneously from the same…
…utility. For more information on the Single-cell Tapestri® Genome Editing Solution, visit https://missionbio.com/applications/genome-editing/ About Mission Bio Mission Bio is a leading life science company, specializing in the advancement…
…of multiple concurrent mechanisms in individual patients underscores the complex biology of resistance and has important implications for rational combination therapy design. This trial was registered at www.clinicaltrials.gov as #NCT02074839….
…B lineage in elderly individuals and patients with lymphoplasmacytic lymphoma, a singular disease for studying lymphomagenesis because of the high prevalence of mutated MYD88. We observed similar accumulation of random…
…early TP53 mutations that occurred in all five patients. Collectively, our data suggests that MPT can overcome technical obstacles for studying tumor evolution using scDNA-seq by profiling information-rich mutation sites….
Covalent (irreversible) Bruton’s tyrosine kinase (BTK) inhibitors have transformed the treatment of multiple B-cell cancers, especially chronic lymphocytic leukemia (CLL). However, resistance can arise through multiple mechanisms, including acquired mutations…
Despite insights gained by bulk DNA sequencing of cancer it remains challenging to resolve the admixture of normal and tumor cells, and/or of distinct tumor subclones; high throughput single-cell DNA…
During the course of infection, human immunodeficiency virus (HIV) maintains a stably integrated reservoir of replication-competent proviruses within the host genome that are unaffected by antiretroviral therapy. Curative advancements rely…
…cellular compartments depending upon co-occurring mutations. These studies provide a path to model sequential mutagenesis and deterministically investigate mechanisms of transformation and oncogenic dependency in the context of clonal evolution….
…precursors remains a challenge with current MRD tools. Herein, we developed a single cell (sc) MRD assay by combining flow cytometric enrichment of the targeted precursor/blast population with integrated scDNA…
…MIF modifies TET2 CH cardiovascular disease risk. Using mitochondrial lineage tracing, we used a novel method to compare gene expression between mutated and non-mutated cells within individual CH patients. We…
…role in hematopoietic stem cell differentiation and monocyte lineage commitment. Together, these data provide a mechanistic insight to the poor prognostic value of clonal hematopoiesis in patients infected with Sars-COV2….
…world’s leaders in life sciences supporting our commercialization efforts,” says Darrin Crisitello, Chief Commercial Officer of Mission Bio. “Leveraging Agilent’s vast US commercial footprint gives us significant reach to additional…
…The Scientist, as well as utilized by researchers at MD Anderson Cancer Center (MDACC) for the largest single-cell study completed to date. Additional studies in therapy resistance and Minimal Residual…
…lines, PBMC cell population responses to mitogenic perturbations, and imatinib impact on retinoblastoma and BCR-ABL driven leukemic cells. This study demonstrates the utility of multimodal resolution in further illuminating cellular…
Acute lymphoblastic leukemia (ALL) is characterized by the presence of chromosomal changes, including numerical changes, translocations, and deletions, which are often associated with additional single-nucleotide mutations. In this study, we…
…machinery of cells, capturing the differential protein expression from cell to cell would benefit the study of cancer biology. Multimodal approaches such as CITE-seq only partially address this problem by…
…of TIBSOVO resistance supported clinical findings of the pivotal TIBSOVO-azacitidine combination trial in IDH1-mutant AML, and the combination was approved by FDA in May 2022. Partnership will continue to generate…
…of single-cell lentiviral vector integration sites and clonal tracking assay provides a unique opportunity to better study longitudinally CAR-T cell clonal dynamics and lead to a more effective therapeutic agent….
Acute myeloid leukemia (AML) is a complex disease with a diverse genetic landscape, leading to treatment challenges and frequent relapses. Measurable residual disease (MRD) testing has become a standard in…
Cancer is a heterogeneous mixture of cells with varied states. The best treatment options require an understanding of the disease state at the cellular level. Single-cell multi-omics reveals the interplay…
…(LOH). Differences in SNVs and CNVs contribute to cancer heterogeneity, making some clonal populations more virulent and drug-resistant than others. Accurately defining clonal populations and reconstructing clonal phylogenies can only…
Genomics data alone provides only partial insights into the cell’s type, state, or function. To obtain a more complete picture and reveal the cell’s phenotypic character, a single-cell multi-omics approach…
…data resolves the complexities of mutation zygosity and co-occurrence in a genome-editing experiment targeting multiple loci. The Tapestri Platform offers a turnkey solution to the complex challenge of characterizing genome-edited…
…more in the same tumor. Studying diverse higher-order genetic interactions that drive bladder cancer is difficult with current models of tumorigenesis and limited by bulk sequencing, which fails to directly…
An average readout from conventional bulk sequencing misses the underlying genetic diversity across cell populations. The Tapestri Platform was developed to enable the accelerated and accessible detection of genomic variability…
…a more comprehensive picture of the disease progression. Distinguishing mutational status at the single-cell level offers precision in diagnosis and informs treatment options. Learn how the Tapestri Single-cell DNA AML…
Recent advancements in genomic analysis of tumors have revealed that cancer disease evolves by a reiterative process of somatic variation, clonal expansion, and selection. To identify lower-prevalence mutations, very high-level…
Co-occurrence and zygosity of mutations in subclonal populations are frequently missed with bulk sequencing. In high-count monoclonal B-cell lymphocytosis (MBL), these mutations were detectable across all patient samples, on average…
Cell and gene therapies are yielding new treatments, which were inconceivable only a few decades ago, for genetic disorders including cancers and inherited diseases. Single-cell DNA sequencing on the Tapestri…
The Tapestri Platform measures transduction efficiency in 1000s of individual cells without the need for clonal outgrowth. This approach allows for the rapid optimization of gene transfer protocols during therapy…
…co-mutations responsible for tumorigenesis. The following are covered: Assessment of precise genetic edits Analysis of the clonal structure & co-mutations of AEL Use of CRISPR and scDNA-seq for disease modeling…
…we show that MGI and Illumina platforms are equally compatible with the Tapestri Platform for single-cell DNA sequencing. A version written in Mandarin is also available here. The following are…
…research centers, pharmaceutical, and diagnostics companies worldwide to develop treatments and eventually cures for cancer. To learn more, visit missionbio.com. Media Contact Consort Partners for Mission Bio missionbio@consortpartners.com Tapestri Cell…
…more on Mission Bio and the Tapestri platform, please visit missionbio.com. About Mission Bio Mission Bio is a life sciences company that accelerates discoveries and cures for a wide range…
…progression and develop more precise therapies. The commercial launch of Mission Bio’s Tapestri Solution for Solid Tumor Research highlights the company’s continued dedication to enabling cancer research at a…
…interrogate every molecule in a cell together, providing a comprehensive understanding of activity from a single sample. Tapestri is the only commercialized multi-omics platform capable of analyzing DNA and protein…
… For more on Mission Bio and the Tapestri platform, please visit missionbio.com. About Mission Bio Mission Bio is a life sciences company that accelerates discoveries and cures for…
…Mission Bio’s commitment to continuously developing innovative single-cell technologies for its pharma customers. “We have seen tremendous uptake and interest from top-tier pharma companies for our blood cancer Pharma…
…Platform, please visit missionbio.com. About Mission Bio Mission Bio is a life sciences company that accelerates discoveries and cures for a wide range of diseases by equipping researchers with…
…Anderson Cancer Center, Broad Institute of MIT and Harvard, and St. Jude Children’s Research Hospital embody Mission Bio’s commitment to advancing hematological research. For a complete list of ASH presentations…
…sciences industry, he brings a unique combination of scientific innovation and strategic business development to the company. His experience in driving organizational transformation and large-scale commercial growth, coupled with his…
…be combined or purchased separately to suit the user’s needs. These assays are compatible with the existing Tapestri Instrument, v3 chemistry, and sample multiplexing: Multiple Myeloma DNA Panel, a…
…and the Tapestri Platform, please visit missionbio.com. Media Contact Consort Partners for Mission Bio missionbio@consortpartners.com Mission Bio Appoints Roman Haehn as Chief Commercial Officer to Drive Market Expansion…
…examine clonal hematopoiesis and minimal residual disease (MRD), respectively. Our Genome Research paper was the first-ever peer-reviewed publication demonstrating scalable single-cell DNA analysis at single-base resolution. And at ASH 2018,…
…effectively combat cancer — to both detect it sooner and develop the most impactful, dynamic therapies — we need to be able to understand it. This means tracking the progression…
…has come more targeted – and in turn, effective – treatments aimed at specific DNA mutations. But still, relapse remains a prominent issue in AML. Evidence suggests that MRD is…
…co-occurrence of multiple edits including on- and off-target events, and rare cell populations, providing the information necessary to optimize editing systems and use them safely. Mouse genome compatibility: Critical to…
…with the new device. The complexity of cancer cannot be overcome without comprehensive tools. Running a large-scale clinical study costs around $40 million, and the pharmaceutical industry is losing…
…patients with multiple-concomitant splicing factor mutations have been observed, challenging our understanding of one of the most common examples of epistasis in hematologic malignancies. In this study, we performed bulk…
…more comprehensive identification of genetic polymorphisms within the targeted loci. MESA requires low amounts of input DNA, minimal prior locus sequence information and enriches the target region without PCR bias…
Dr. Cathy Smith from UCSF provides a case study on single-cell sequencing of polyclonal resistance to FLT3 inhibitors in acute myeloid leukemia (AML). She presents data taken over a period…
…Linde Miles, of Ross Levine’s lab at Memorial Sloan Kettering Cancer Center, shares findings from her study where she immunophenotyped and genotyped AML samples to track the order of mutations…
…case of relapse. ALL is the most common cancer in children and shows extensive genetic intra-tumoral heterogeneity. This heterogeneity may be the underlying reason for an incomplete response to treatment…
Dr. Takahashi from MD Anderson Cancer Center presents his findings using single-cell sequencing from a study of 70 AML patients demonstrating clonal remodeling at relapse. Furthermore, divergent clones with a…
…in the clinic and the differences between amplicon and hybridization methods. While Dr. Alexander Perl, from the University of Pennsylvania, discusses the findings in their collaborative CHRYSALIS study of the…
Dr. Cathy Smith from UCSF provides a case study on single-cell sequencing of polyclonal resistance to FLT3 inhibitors in acute myeloid leukemia (AML). She presents data taken over a period…
In this early proof-of-concept study, Dr. Koichi Takahashi from MD Anderson uses the newly available Tapestri Platform for high-throughput single-cell DNA sequencing of acute myeloid leukemia (AML) tumors. Sophisticated microfluidics…
…Bio Tapestri Platform for single-cell analysis. See how researchers are using this groundbreaking technology to study single-cell multi-omics of DNA and Protein for the first time in a high-throughput fashion….
…the relative fitness of different clones, and at dominant versus minor subclones. All of those features come that you could never get out of bulk sequencing and really the data,…
…and in which cellular compartment they reside. This is the type of work the Tapestri instrument is made for. By combining DNA mutational analysis and immunophenotyping, one can simultaneously measure…
…monitor clonal evolution, as this approach requires complex computational analysis. Researchers could greatly expand their knowledge of changes occurring at the DNA level by the addition of single-cell DNA-seq. Moreover,…
…ASXL1, collectively referred to as DTA mutations (incorporating the first letter of each gene). HSCs with these mutations have a competitive advantage, such that they are able to self-renew more…
What are the emerging trends and challenges with targeted therapies for blood cancer today? How does single-cell analysis impact the study of therapy response and resistance mechanisms? We invited two…
…a study she co-authored that was published in Blood, “Modeling and targeting of erythroleukemia by hematopoietic genome editing,” in which she developed faithful experimental models of acute erythroid leukemia (AEL)…
…Dr. Smith’s lab used serial single-cell DNA sequencing (using Mission Bio’s Tapestri Platform) to assess the clonal architecture of AML through treatment. She also discusses a third study using DNA…
…using single-cell analysis to elucidate clonal evolution, including the ability to distinguish which mutations occur in the same clone(s), accurately measure clonal complexity, and definitively determine the order of mutations….
…response, or no response at all. To help answer these questions, Mission Bio has opened a Pharma Applications Development (PAD) lab specializing in working with pharmaceutical companies to develop assays…
…RPA1E240K and RPA1V227A proteins exhibit increased binding to single-strand and telomeric DNA, implying a gain in DNA-binding function while RPA1T270A has binding properties similar to wild type protein. To study…
…complex mechanisms of resistance to quizartinib Investigated mechanisms of resistance to quizartinib in patients with FLT3-ITD mutated AML. Wang, F. et al., Nature Communications Leukemia stemness and co-occurring mutations drive…
…can act as biomarkers to predict survival and improved treatment options. A recent study in Cell which leveraged the newly finalized survival data in the TCGA identified that mutations in…
…dormant for six to 19 years until rapid expansion at transformation. He will also overview the findings from the study that suggest that CLL evolution to RT is driven by…
Over the past decade, numerous advances in biotechnology have translated into improvements in the medical arena. Yet, limitations in analytical tools still remain and present significant roadblocks to the study…
…lower complete remission (CR) rates, higher relapse rates and inferior overall survival (OS) compared with patients with mutated WT1 but no FLT3-ITD. Though WT1 mutations are common in adult AML,…
…Sickle Disease. However, the power of CRISPR comes hand-in-hand with a complex challenge – the inherent heterogeneity in editing outcomes. This variability can pose a significant hurdle for researchers aiming…
…investment group focused solely on biotechnology, genomics, diagnostics, medical device and mobile health companies. Since 2005, LSA and its affiliates have invested over $50 million in 50 companies which have…
Cancer is a complex disease with a mix of cells with varied states, and understanding of the disease state at the cellular level is required for better therapies. A single-cell…
…missed by standard bulk sequencing or identifying co-mutation patterns and zygosity in subclones, Tapestri Single-cell DNA panels and protein panels can be applied across a wide range of discovery and…
…the clonal heterogeneity of cancers or the performance of gene-editing protocols across thousands of single cells. Our Tapestri Designer software allows you to complete custom designs quickly and easily. …
High-throughput single-cell DNA sequencing is essential to assess genetic variations in rare cells and better understand the role they play in the evolution of tumor progression. To address these challenges…
It is essential to develop new capabilities for assessing genetic variation present in rare cells and to better understand the role that these cells play in the evolution of tumor…
Many stages of hematopoietic differentiation provide multiple opportunities for mutations that lead to distinct tumor subtypes. However, standard bulk population sequencing is hard to identify rare alleles or determine whether…
Understanding tumor heterogeneity and clonal evolution has major implications in oncology research. Both chromosomal structural change/copy number alteration/variation (CNA/CNV) and driver gene mutation events are critical in cancer initiation and…
To improve variant calling and minimal residual disease (MRD) detection we developed a novel consensus sequence-based method for correcting the errors and reducing the false-positive rates….
…in targeted therapy selection and disease monitoring. Single-cell sequencing has the potential to provide unique insights on the cellular and genetic composition, drivers, and signatures of cancer at unparalleled sensitivity….
High-throughput single-cell DNA sequencing allows for the detection of rare mutations in cells and identification of sub-clones defined by co-occurrence of mutations. The big challenge with multiplex sequencing at the…
…inadequate to fully characterize somatic variation buried in the landscape of cellular populations. Single-cell targeted DNA sequencing provides an essential solution to elucidate and map genomic variation in such materials….
AML has a poor prognosis, mainly due to relapse. Single-cell DNA sequencing technologies like the Mission Bio Tapestri Platform enable us to understand the clonal heterogeneity of AML patient samples…..
Recent advancements in genomic analysis of tumors have revealed that cancer disease evolves by a reiterative process of somatic variation, clonal expansion, and selection. Therefore, intra- and inter-tumor genomic heterogeneity…
Single-cell technologies have advanced our approach to precision medicine, improving our understanding of the genetic variation and drivers of cancer with sensitivity that bulk sequencing cannot provide….
Genomics data alone provides only partial insights into the cell’s type, state, or function. To obtain a more complete picture and reveal the cell’s phenotypic character, a multi-omics approach is…
Single-cell sequencing elucidates unique insights in understanding intratumor heterogeneity and clonal evolution. Both chromosomal structural change/copy number alteration/variation (CNA/CNV) and driver gene mutation events appear somatically at the early stages…
…resolution of the disease at the cellular level, revealing the interplay between genotype and phenotype. The Tapestri Platform enables comprehensive identification of cell subpopulations through single-cell multi-omics profiling. The platform…
Through single-cell sequencing technologies, it is now possible to interrogate thousands of cells in a single experiment for genetic variability. Single-cell DNA platforms like Tapestri are still susceptible to errors…
High throughput single cell DNA targeted sequencing enables the detection of rare mutations in cells and the identification of subclones defined by co-occurrence of mutations. The big challenge with multiplex…
We recently spoke with Dr. Cummins about her research, use of the Tapestri Platform, and thoughts on single-cell multi-omics and cell therapies for leukemias….
We recently spoke with Dr. Smith about her research, use of the Tapestri Platform, and thoughts on the clinical potential for routine, high-throughput single-cell DNA analysis….
On World AML Day, we had the pleasure of being joined by Dr. Ross Levine of Memorial Sloan Kettering Cancer Center to discuss the use of single-cell technology and how…
…DNA to reveal extensive proteogenomic decoupling in leukemia patient samples. Now cell types and cell states are revealed by combining protein markers with DNA analysis from thousands of single cells….
…better understand which combinations of mutations are important for driving bladder cancer, Dr. John Lee from the Fred Hutch Institute combines sophisticated genome editing, organoid, and mouse model approaches with…
Minimal Residual Disease (MRD) detection and monitoring hold great promise to be used in clinical trials and beyond patient therapy selection. If single nucleotide variants (SNVs) are detected early on,…
Challenging the dogma that single nucleotide variants (SNVs) in RNA splicing factors do not occur in the same cell due to their synthetic lethal interactions and/or convergent effects, Dr. Justin…
Have you ever wondered what were the exact indels that were made to the DNA after genome editing experiments? Have you wondered what percentage of the cells had certain edits?…
Cancer is a complex disease that continuously evolves in response to environmental pressures. The dynamism and heterogeneity of tumors have significant clinical implications. In this eBook, review how single-cell DNA…
Genomics data alone provides only partial insights into the cell’s type, state, or function. To obtain a more complete picture and reveal the cell’s phenotypic character, a multi-omics approach is…
…genetic composition. This poster presents the process of Mission Bio’s Tapestri Platform, which enables high-throughput targeted DNA sequencing in single cells to obtain single-nucleotide variation (SNV) and copy number variation…
This poster demonstrates the capability of the Tapestri Platform multi-omics workflow (which analyzes the DNA and protein information from the same cells) to discriminate cell populations. Using a two-donor PBMC…
…we show that MGI and Illumina platforms are equally compatible with the Tapestri Platform for single-cell DNA sequencing. A version written in English is also available here. The following are…
Cell and gene therapies are yielding new treatments, which were inconceivable only a few decades ago, for genetic disorders including cancers and inherited diseases. Single-cell DNA sequencing on the Tapestri…
The Tapestri Platform provides an unprecedented level of quantification of DNA integrations in significantly less time compared to other techniques such as qPCR and does so at single-cell resolution. These…
At Mission Bio, we applaud the research that has been accomplished over the years using our innovative single-cell multi-omics platform, Tapestri. We compiled a list of publications that utilize single-cell…
The inclusion of intracellular protein detection enables the measurement of pivotal proteins in cancer mechanisms, including apoptosis (BCL2 family proteins), transcription factors (GATA3), tumor suppressors (TP53), as well as phosphorylated…
There is a lack of data on CNV in single cells in solid tumor samples. We demonstrate single-cell DNA sequencing using the Tapestri instrument for solid tumor samples and an…
CRISPR is a powerful tool for the development of novel cell and gene therapies. Despite its ability to precisely alter the genome, CRISPR can yield off-target edits and rare chromosomal…
…of Excellence for Solid Tumor. • The Tapestri Platform, combined with the new Tapestri Single-cell CNV Analysis Tool, enables co-measurement of single-cell SNVs and CNVs across thousands of single cells….
…for 1/3rd of all meningiomas. NF2-wild type meningiomas are commonly associated with mutations in SMO, POLR2A, PIK3CA, AKT1, and KLF4 mutations, the latter both occur regularly with TRAF7 mutations. The…
Internal tandem duplication of the Feline McDonough Sarcoma (FMS)-like tyrosine kinase 3 (FLT3-ITD) is one of the most clinically relevant mutations in acute myeloid leukemia (AML), with a high FLT3-ITD…
…efficacy and safety. Key safety and efficacy attributes need to be accurately measured prior to reintroducing modified T cells back into patients, including CAR transgene copy number or viral vector…
…of Excellence for Solid Tumor. • The Tapestri Platform, combined with the new Tapestri Single-cell CNV Analysis Tool, enables co-measurement of single-cell SNVs and CNVs across thousands of single cells….
Accelerate your hematologic oncology projects with a dedicated partner across the drug development pipeline through the Pharma Assay Development Biomarker Discovery pilot program….
Servier worked with Mission Bio’s Pharma Assay Development (PAD) services to utilize the Tapestri® single-cell DNA sequencing technology to serially assess hundreds of samples from patients with IDH1-mutated AML who…
…globe the power to interrogate genotype and immunophenotype together in individual cells, providing a comprehensive understanding of activity from a single sample. Tapestri® is the only commercialized multi-omics platform capable…
…patients, the same blood samples were also studied for comparison by Tapestri single-cell DNA sequencing (scDNAseq). The clonal architectures derived by the 2 methods showed good overall concordance. scDNAseq showed…
…clonal outgrowth steps and hours of computational work. With the Tapestri single-cell platform you can rapidly capture genome editing outcomes and confidently validate your engineered cell therapy or CRISPR-based disease…
…gene editing, Tapestri can co-measure these attributes simultaneously in each cell. The platform’s powerful multi-omics capability enables the co-analysis of DNA and cell-surface proteins so you can evaluate cell type/…
…viral vector copy number (VCN), needs to be accurately measured. Yet conventional methods for measuring gene transfer lack the resolution and representation to truly reflect sample composition and either report…
Cell and gene therapies are notoriously difficult to characterize. Yet, early and thorough characterization is key to advancing therapeutic programs quickly with minimal risk of safety issues or clinical holds….
…was entirely surmised by mutated clones. BP originated from increasing clonal complexity, either on top or independent of a driver mutation, through acquisition of novel mutations as well as accumulation…
…but also identify putative DNA or protein targets for salvage therapy. By combining high sensitivity with multiomics, this assay provides researchers with comprehensive and clinically actionable insights into AML MRD….
…MRD across thousands of individual cells, providing clonal insight in tandem with immunophenotype from rare residual disease cells. These high-resolution, integrated molecular profiles bring unprecedented clarity to the complex biology…
Acute myeloid leukemia (AML) is a dynamic disease with a diverse genetic landscape. Complex heterogeneity of clonal architecture and genotypic and phenotypic drifts that can occur during treatment explain why…
…surface protein expression. We show here complex clonal evolution of MM in two patient samples as copy gains and losses were sequentially acquired and correlated with expression changes of MM…
Mission Bio’s Tapestri® Genome Editing Solution offers a comprehensive solution for high-throughput analysis of genomic edits at single-cell resolution. Here, we showcase the robust performance of the pipeline for both…
…heterozygous, compound heterozygous), and their functional impact all contribute to the layer of complexity in the mosaicism of editing outcomes. Current genome editing analyses primarily rely on bulk methods, which,…
…and surface protein expression. We show here complex clonal evolution of MM in two patient samples as copy gains and losses were sequentially acquired and correlated with expression changes of…
…(homozygous, heterozygous, compound heterozygous), and their phenotypic effects all contribute to the layer of complexity to the mosaicism of editing’s outcomes. Current genome editing analyses primarily rely on bulk methods…
Sample multiplexing allows multiple samples to be pooled and processed simultaneously in a single run on the Tapestri Platform to achieve higher throughput and cost-efficiency while maintaining the same robust…
Sample multiplexing allows multiple samples to be pooled and processed simultaneously in a single run on the Tapestri Platform to achieve higher throughput and cost-efficiency while maintaining the same robust…
Tapestri single-cell multiomics analysis can transform how you tackle the complexities of multiple myeloma (MM) and its precursor stages by integrating genomic, proteomic, and clonotypic subclonal assessment with single-cell resolution,…
Genome editing, in which precise changes can be made to the genome, has opened the door to vast opportunities in areas such as cell and gene therapy development, functional genomics,…
…long-term surveillance. Being able to more comprehensively identify low-frequency subclones that may result in frank disease or resistance would enable more direct application of precision therapies. Here, we present proof…
…from the diagnostic population. These methods are commonly discordant, leading to clinical questions for individual surveillance and treatment. Combining these assays with single-cell resolution overcomes these limitations and reveals subclonal…
…long-term surveillance. Being able to more comprehensively identify low frequency subclones that may result in frank disease or resistance would enable more direct application of precision therapies. Here, we present…
